Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1064
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYap, Celene Y. L.*
dc.contributor.authorTaylor, David McD*
dc.contributor.authorKnott, Jonathan C.*
dc.contributor.authorTaylor, Simone E.*
dc.contributor.authorPhillips, Georgina A.*
dc.contributor.authorKarro, Jonathan*
dc.contributor.authorChan, Esther W.*
dc.contributor.authorKong, David C. M.*
dc.contributor.authorCastle, David J.*
dc.date.accessioned2017-10-10T03:06:14Z-
dc.date.available2017-10-10T03:06:14Z-
dc.date.issued2017-
dc.identifier.govdoc01031en_US
dc.identifier.issn0965-2140en_US
dc.identifier.urihttp://hdl.handle.net/11054/1064-
dc.description.abstractAIM: To examine the efficacy and safety of (1) midazolam-droperidol versus droperidol and (2) midazolam-droperidol versus olanzapine for methamphetamine-related acute agitation. DESIGN AND SETTING: A multi-centre, randomized, double-blind, controlled, clinical trial was conducted in two Australian emergency departments, between October 2014 and September 2015. PARTICIPANTS: Three hundred and sixty-one patients, aged 18-65 years, requiring intravenous medication sedation for acute agitation, were enrolled into this study. We report the results of a subgroup of 92 methamphetamine-affected patients. INTERVENTION AND COMPARATOR: Patients were assigned randomly to receive either an intravenous bolus of midazolam 5 mg-droperidol 5 mg combined, droperidol 10 mg or olanzapine 10 mg. Two additional doses were administered, if required: midazolam 5 mg, droperidol 5 mg or olanzapine 5 mg, respectively. MEASUREMENTS: The primary outcome was the proportion of patients sedated adequately at 10 minutes. Odds ratios with 95% confidence intervals (ORs, 95% CI) were estimated. FINDINGS: The baseline characteristics of patients in the three groups were similar. At 10 minutes, significantly more patients in the midazolam-droperidol group [29 of 34 (85.3%)] were sedated adequately compared with the droperidol group [14 of 30 (46.7%), OR = 6.63, 95% CI = 2.02-21.78] or with the olanzapine group [14 of 28 (50.0%), OR 5.80, 95% CI = 1.74-19.33]. The number of patients who experienced an adverse event (AE) in the midazolam-droperidol, droperidol and olanzapine groups was seven of 34, two of 30 and six of 28, respectively. The most common AE was oxygen desaturation. CONCLUSION: A midazolam-droperidol combination appears to provide more rapid sedation of patients with methamphetamine-related acute agitation than droperidol or olanzapine alone.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2017-05-16T05:11:03Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2017-10-10T03:06:14Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2017-10-10T03:06:14Z (GMT). No. of bitstreams: 0 Previous issue date: 2017en
dc.titleIntravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trial.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleAddictionen_US
dc.bibliographicCitation.volume112en_US
dc.bibliographicCitation.issue7en_US
dc.bibliographicCitation.stpage1262en_US
dc.bibliographicCitation.endpage1269en_US
dc.subject.healththesaurusBENZODIAZEPINESen_US
dc.subject.healththesaurusDROPERIDOLen_US
dc.subject.healththesaurusEMERGENCY CAREen_US
dc.subject.healththesaurusMETHAMPHETAMINEen_US
dc.subject.healththesaurusMIDAZOLAMen_US
dc.subject.healththesaurusOLANZAPINEen_US
dc.subject.healththesaurusPSYCHOMOTOR AGITATIONen_US
dc.subject.healththesaurusSEDATIONen_US
dc.date.issuedbrowse2017-01-01-
dc.identifier.doi10.1111/add.13780en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.